ENB Therapeutics
  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us
Select Page

IND approval received for lead product ENB-003

Nov 17, 2020 | Uncategorized

January 17, 2020

ENB Therapeutics receives IND approval from the FDA for our Phase 1/2 trial evaluating the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. This is a major milestone for ENB and allows our clinical trial to be initiated as planned later this year.

Recent Posts

  • ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
  • Early efficacy signals in ovarian cancer patients in ongoing Ph1 trial: Poster reporting findings presented at SITC 2020 Annual Meeting
  • ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase 1 Clinical Trial of ENB-003 in Combination with Pembrolizumab
  • IND approval received for lead product ENB-003
  • ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors

Recent Comments

  • ENB-003 with Keytruda Shows Promise Against Advanced Solid Tumors – BioNewsFeeds on Pipeline
  • ENB-003 with Keytruda Shows Promise Against Advanced Solid Tumors – BioNewsFeeds on Pipeline
  • Mr WordPress on Start up announcement

Archives

  • February 2021
  • November 2020
  • February 2019
  • September 2018
  • April 2016
  • January 2016
  • June 2015

Categories

  • Press Releases
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Explore

  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us

Recent Posts

Click Here

Contact Us

ENB Therapeutics
Alexandria Center For Life Sciences,
Launch Labs
430 E 29th Street, 14th Floor
New York, NY 10016
(212) 792-2317
info@enbpharma.com

Copyright © 2019 ENB Therapeutics. All rights reserved.